Aida Pharmaceuticals, Inc. (OTCPK: AIDA)
Health Care · Pharmaceuticals · CN
$—
— today · — 1Y
Aida Pharmaceuticals, Inc. (OTCPK: AIDA) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $8.13K and employs 450 people.
trading between 0.00 and 0.00.
Tweenvest scores Aida Pharmaceuticals, Inc. across four factors: value 48/100. Its strongest factor is value.
AIDA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $8.13K
- Revenue (TTM)
- $40.51M
- P/E
- —
- EPS
- -0.08
- Dividend yield
- —
- Beta (5Y)
- 22.47
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 27.00M
- Employees
- 450
- Next earnings
- —
About Aida Pharmaceuticals, Inc.
Aida Pharmaceuticals, Inc., together with its affiliates, operates extensively throughout mainland China, specializing in the entire spectrum of pharmaceutical and genetic product development. This encompasses formulation, clinical trials, regulatory registration, manufacturing, sales, and marketing. The company's diverse product range includes antibiotics, cardiovascular medicines, and anti-cancer drugs. These are available in various forms, such as injectable powders, intravenous liquids, capsules, tablets, and ointments. Notable products feature Etimicin Sulfate, provided as an injectable powder, and rh-Apo2l, a biopharmaceutical therapy targeting cancers. Established in 1999, Aida Pharmaceuticals, Inc. is headquartered in Hangzhou, China.
- ISIN
- US0087211027
- Founded
- 1999
- Listed since
- Sep 26, 2005
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.22 | -0.96% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.15 | +0.29% |
Figures last refreshed Aug 18, 2026.